These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 20065189)

  • 61. Targeting RET receptor tyrosine kinase activation in cancer.
    Phay JE; Shah MH
    Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Management of hereditary medullary thyroid carcinoma.
    Pappa T; Alevizaki M
    Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH; Robinson BG; Learoyd DL
    Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
    Postel-Vinay S; Schlumberger M; Soria JC
    Ann Oncol; 2013 Sep; 24(9):2201-4. PubMed ID: 23986546
    [No Abstract]   [Full Text] [Related]  

  • 66. Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
    Machens A; Dralle H
    J Clin Oncol; 2010 Oct; 28(28):e534: author reply e535-6. PubMed ID: 20713862
    [No Abstract]   [Full Text] [Related]  

  • 67. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ; Magalhães PKR
    Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
    Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
    Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
    Werner RA; Schmid JS; Muegge DO; Lückerath K; Higuchi T; Hänscheid H; Grelle I; Reiners C; Herrmann K; Buck AK; Lapa C
    Medicine (Baltimore); 2015 Nov; 94(45):e2016. PubMed ID: 26559299
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Durability of Response With Selpercatinib in Patients With
    Wirth LJ; Brose MS; Subbiah V; Worden F; Solomon B; Robinson B; Hadoux J; Tomasini P; Weiler D; Deschler-Baier B; Tan DSW; Maeda P; Lin Y; Singh R; Bayt T; Drilon A; Cassier PA
    J Clin Oncol; 2024 Sep; 42(27):3187-3195. PubMed ID: 39094065
    [No Abstract]   [Full Text] [Related]  

  • 71. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
    Frank-Raue K; Fabel M; Delorme S; Haberkorn U; Raue F
    Eur J Endocrinol; 2007 Aug; 157(2):215-20. PubMed ID: 17656601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
    Starenki D; Park JI
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1529-40. PubMed ID: 23509102
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
    Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
    Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
    [TBL] [Abstract][Full Text] [Related]  

  • 75. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 76. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Karlin N; Sideras K; Morris JC; McIver B; Hay I; Fatourechi V; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Cher Goh B; Isham CR; Harris P; Erlichman C;
    J Clin Endocrinol Metab; 2014 May; 99(5):1687-93. PubMed ID: 24606083
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
    Lim SM; Chang H; Yoon MJ; Hong YK; Kim H; Chung WY; Park CS; Nam KH; Kang SW; Kim MK; Kim SB; Lee SH; Kim HG; Na II; Kim YS; Choi MY; Kim JG; Park KU; Yun HJ; Kim JH; Cho BC
    Ann Oncol; 2013 Dec; 24(12):3089-94. PubMed ID: 24050953
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 79. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients.
    Long KL; Etzel C; Rich T; Hyde S; Perrier ND; Graham PH; Lee JE; Hu MI; Cote GJ; Gagel R; Grubbs EG
    Fam Cancer; 2017 Apr; 16(2):283-289. PubMed ID: 27864651
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
    Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
    Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.